Life Sciences

Understand and manage your R&D, commercial and manufacturing asset portfolios in a more holistic manner.

With healthcare reforms’ greater regulatory burdens, cost-sensitive payers’ tightened reimbursement, and fewer first-in-class opportunities in major therapeutic pipelines – there’s no doubt these are challenging times for Life Sciences companies.

A long history of PPM consulting for major Life Sciences companies
As pressures only grow to increase R&D, commercial and manufacturing efficiencies while keeping the engines in full throttle – stakeholders in the pharmaceutical industry need to view, understand and manage their assets with a more holistic perspective in mind. As recognized thought-leaders in integrated portfolio management, UMT is uniquely positioned to leverage our industry knowledge and established best practices to be strategic partners in addressing the challenges of this rapidly changing industry.

Effective R&D Management

Increased regulations along with the pressure to provide value-based medicines with greater efficacy and safety relative to competitors has significantly increased the size and duration of clinical trials, which, in turn, has significantly increased the cost burden on Life Sciences companies.

Phase III trials for major therapeutic areas such as cardiovascular and metabolic disorders can cost over a billion dollars as they require enrollment of thousands of patients and tracking clinical outcomes over a long period of time before obtaining regulatory approval.

UMT has successfully worked within Life Science's R&D functions such as Clinical Operations, Clinical Management, Clinical Outsourcing, Medical Writing, CSPV and Clinical Program Management to provide solutions that facilitate effective end-to-end management of the R&D portfolio. Our solutions allow visibility into the status of clinical development across internal functions as well as outsourced functions such as CROs.

We ensure that our R&D program and portfolio management solutions utilize optimized processes that allow our clients to deliver a greater number of high-quality clinical studies at lower costs via:

Visibility into key horizontal and vertical milestones Tracking of metadata elements
  • Protocol
  • Indication
  • Compound
  • Therapeutic area
  • Enrollment by region
  • Enrollment by country
  • Enrollment by site
Aggregate level views across upcoming submissions
  • Resources
  • Key dates
  • Status updates
  • Risks
  • Functional/Executive
Improved Launch Management

A well-executed launch is one of the most reliable predictors for reaching target sales. A launch portfolio comprises of a variety of projects by different functional areas from Regulatory, Medical Affairs, Market Access, Supply Chain to Sales & Marketing, with crisscrossing timelines and complex interdependencies of risks and deliverables.  While it is increasingly important for pharmaceuticals to perform outstandingly at launch execution, it is very difficult to accomplish. More than 60% of launches perform below target sales in the first year and recovery takes years, damaging both the top and bottom lines of the brand.

UMT works with Life Sciences companies to build comprehensive project management platforms to capture information on the entire launch portfolio, including parallel projects of various functional areas, critical interdependencies and timelines for launch deliverables – from filing and analyzing the Phase III trial results through transitioning to engagement of key stakeholders and opinion leaders and there on to the various operations of commercial launch planning and execution. Solutions include: 

Holistic process design and data models Sophisticated and comprehensive reporting tools
  • Assimilate and manage product launch portfolio
  • KPIs for each phase of product development
  • Tie brand-specific strategic drivers to the each project
Standard analytical platform to record and coordinate
  • Collaborative activities
  • Interdependent timelines
Optimized Strategic Portfolios

More drugs in more major therapeutic areas are reaching LOE and patent cliffs. Longer trials are needed to show safety and efficacy and there are fewer unmet needs making it very challenging for Life Sciences companies to be innovative. Furthermore, Phase III trials are an extremely expensive enterprise.  Faced with many options, it is imperative that Life Sciences companies invest in the right candidate drugs or devices to maximize the chances of a successful launch.

UMT works with organizations in the industry to help identify the optimal portfolio, enhance chances of successful launches and maximize operational efficiency:

Identifying business drivers Project evaluation and selection
  • Strategic imperatives
  • Prioritization of drivers and constraints
  • Alignment of tactics to strategic drivers
Portfolio Selection Scenario planning and comparative analyses of various portfolios
  • Optimization using the efficient frontier
  • End-to-end life cycle view of each inline and pipeline brand
Enhanced Financial Governance

As in many industries, the Life Sciences sector is also facing several challenges that are eroding both top line revenue (e.g., loss of exclusivity) as well as profit margins (reimbursement pressure). Life Sciences companies need to constantly innovate their financial management to adapt to these challenges.

UMT works with Life Sciences companies to provide the following services:

Define and Design Corporate and strategic portfolio prioritization and optimization
  • Strategy and best practices
  • Practical tools to enhance financial governance of projects and portfolios
  • Facilitate the product/portfolio investment process
Visibility through advanced reporting Efficient procurement strategies
  • Surface key risks of budgetary over-runs for large programs/portfolios
  • Align to brands or corporate capabilities (e.g. IT, services)
  • Advanced resource and capability management
  • Reporting to monitor key dynamics of sourcing and procurement by brands/portfolios


Better Manufacturing Resourcing

Manufacturing plays an important role in balancing the creation of new efficiencies with agile decision-making and resource allocation to meet rapidly changing business demands. It’s a never ending struggle to decrease time to commercialization for new products and maintain compliant and reliable supplies of established products at ever decreasing unit costs in the face of inspections, deviations, and other regulatory obligations. UMT has deep experience and expertise helping manufacturing divisions to better allocate indirect labor and to prioritize and align their efforts to strategic, tactical and site-level initiatives. The results can be significantly increased returns from investments in projects that support efforts like new product introductions, technology transfers, manufacturing changes, regulatory commitments and production volume changes.

Project portfolio planning, monitoring and control Proactive risk management
  • Advanced reporting of key milestones, risks and interdependencies 
  • Current and historical risk trends
Manage run-the-business / strategic projects Support manufacturing operating innovation models
  • Resource management
  • Capacity planning
  • Hoshin-Kanri